As expected, urothelial carcinoma, renal cell carcinoma, and melanoma patients with high TIIClnc signature scores were prone to benefit more from anti-PD-1, anti-PD-L1, or anti-CTLA-4 immunotherapy, respectively. The gene discussed is CTLA4; the disease is urothelial carcinoma.